Drug General Information
Drug ID	D0N9VZ
Former ID	DND000038
Drug Name	ADL-5747
Indication	Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]		Phase 2	[522936]
Company	Pfizer
Structure		Download 2D MOL
Target and Pathway
Target(s)	Delta-type opioid receptor	Target Info	Agonist	[543762]
KEGG Pathway	cGMP-PKG signaling pathway
	Sphingolipid signaling pathway
	Neuroactive ligand-receptor interaction
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Enkephalin release
	Opioid proenkephalin pathway
	Opioid proopiomelanocortin pathway
Reactome	Peptide ligand-binding receptors
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522936	ClinicalTrials.gov (NCT01058642) Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Patients With Postherpetic Neuralgia. U.S. National Institutes of Health.
Ref 543762	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.